Improving outcomes of first‐episode psychosis: an overview. Issue 3 (21st September 2017)

• Record Type: Journal Article
• Authors: Fusar‐Poli, Paolo; McGorry, Patrick D.; Kane, John M.
• Is Part Of: World psychiatry. Volume 16:Issue 3(2017:Oct.)
• Page Start: 251
• Page End: 265
• Publication Date: 2017-09-21
• Subjects: Psychosis -- schizophrenia -- psychosis risk -- clinical high risk -- first episode psychosis -- universal prevention -- selective prevention -- indicated prevention -- outcomes -- clinical staging; Psychiatry -- Periodicals; Mental illness -- Periodicals; 616.89005
• DOI: 10.1002/wps.20446
• Languages: English
• ISSNs: 1723-8617

Abstract

Abstract : Outcomes of psychotic disorders are associated with high personal, familiar, societal and clinical burden. There is thus an urgent clinical and societal need for improving those outcomes. Recent advances in research knowledge have opened new opportunities for ameliorating outcomes of psychosis during its early clinical stages. This paper critically reviews these opportunities, summarizing the state‐of‐the‐art knowledge and focusing on recent discoveries and future avenues for first episode research and clinical interventions. Candidate targets for primary universal prevention of psychosis at the population level are discussed. Potentials offered by primary selective prevention in asymptomatic subgroups (stage 0) are presented. Achievements of primary selected prevention in individuals at clinical high risk for psychosis (stage 1) are summarized, along with challenges and limitations of its implementation in clinical practice. Early intervention and secondary prevention strategies at the time of a first episode of psychosis (stage 2) are critically discussed, with a particular focus on minimizing the duration of untreated psychosis, improving treatment response, increasing patients' satisfaction with treatment, reducing illicit substance abuse and preventing relapses. Early intervention and tertiary prevention strategies at the time of an incomplete recovery (stage 3) are further discussed, in particular with respect to addressing treatment resistance, improving well‐being and social skills with reduction of burden on the family, treatment of comorbid substance use, and prevention of multiple relapses and disease progression. In conclusion, to improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre‐emptive interventions to high‐risk groups identified across the early stages of the disorder. Only a systematic implementation of these models of care in the national health care systems will render these strategies accessible to the 23 million people worldwide suffering from the most severe psychiatric disorders.